BACM
VRTX icon

Blue Arrow Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Blue Arrow Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-18,138
Closed -$2.15M – 204
2014
Q4 		$2.15M Sell
18,138
-1,635
-8% -$184K 0.24% 100
2014
Q3 		$2.22M Buy
+19,773
New +$1.88M 0.24% 111

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Blue Arrow Capital Management's VRTX Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2015, closing a stake of 18,138 shares — an estimated $2.15M sold.

Blue Arrow Capital Management first reported a position in VRTX in Q3 2014 and held it in 2 quarters. The position peaked at $2.22M in Q3 2014. 479 funds tracked by Wall St. Rank hold VRTX as of Q1 2015.

  • Blue Arrow Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 18,138 Vertex Pharmaceuticals shares in Q1 2015, an estimated $2.15M.
  • Blue Arrow Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Blue Arrow Capital Management's Vertex Pharmaceuticals position peaked at $2.22M in Q3 2014.
  • 479 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.